共 68 条
[1]
Siegel R(2017)Cancer statistics, 2017 CA Cancer J Clin 67 7-30
[2]
Miller KD(2007)Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy Curr Oncol 14 S20-S40
[3]
Jemal A(2003)Aromatase inhibitors in breast cancer N Engl J Med 348 2431-2442
[4]
Derzko C(2013)Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer Menopause. 20 162-168
[5]
Elliott S(2016)American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care guideline J Clin Oncol 34 611-635
[6]
Lam W(2015)A practical solution for dyspareunia in breast cancer survivors: a randomized controlled trial J Clin Oncol 33 3394-3400
[7]
Smith IE(2014)Locating pain in breast cancer survivors experiencing dyspareunia: a randomized controlled trial Obstet Gynecol 123 1231-1236
[8]
Dowsett M(2016)Vaginal estrogen products in hormone receptor-positive breast cancer patients on aromatase inhibitor therapy Breast Cancer Res Treat 157 203-210
[9]
Baumgart J(2006)Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors Ann Oncol 17 584-587
[10]
Nilsson K(2011)Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients Climacteric. 14 339-344